Stockpolly
Search
Delisting risk
OGEN · AMEX · Biotechnology

Oragenics (OGEN)

Developing an intranasal concussion treatment candidate through outsourced clinical development.

$0.5176
Pre-market−0.01 (−1.22%)
At close$0.5240(+5.01%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue110000000000
Gross profit−110000000000
22223223223
Research & development111112001111
22122212221
General & administrative22122212221
Other expenses−110000000000
Operating income−13−2−2−2−3−2−2−3−2−2−3
000000−10000
Interest income00000000000
Interest expense00000010000
Other non-operating income00000000000
Income before tax−13−2−2−2−3−2−2−3−2−2−3
Income tax expense00000000000
Net income from continuing operations−13−2−2−2−3−2−2−3−2−2−3
Net income−13−2−2−2−3−2−2−3−2−2−3
EPS, basic−$4.92−$0.70−$0.51−$0.38−$0.51−$3.60−$3.10−$1.96−$0.54−$0.51−$0.57
EPS, diluted−$4.92−$0.70−$0.51−$0.38−$0.51−$3.60−$3.10−$1.96−$0.54−$0.51−$0.57
Weighted average shares, basic33577100444
Weighted average shares, diluted33577100444
EBITDA−13−2−2−2−3−2−20−2−2−3
Depreciation & amortization00000003000
EBIT−13−2−2−2−3−2−2−3−2−2−3